Biggest News Aggregation in the World
📰 Aldafermin News

Aldafermin News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Aldafermin. Real-time updates on events, politics, business and more.

NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023

Aldafermin demonstrated statistically significant reductions in serum 7αC4 and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-DAround 25-50% of patients with... | May 8, 2023
United States Davidj Woodhouse Exchange Commission Biopharmaceuticals Inc Digestive Disease Week Mayo Clinic

NGM Bio's NASH drug fails in Phase 2; focus shifts to Merck-partnered programs

An NGM Biopharmaceuticals drug candidate for the fatty liver disease NASH failed a Phase 2b study less than a year after the company reported positive results from an earlier mid-stage study. The biotech will now focus on programs in eye diseases and cancer that are partnered with Merck.
Intercept Pharmaceuticals Gilead Sciences Novo Nordisk International Liver Congress New Jersey Based Merck Weight Loss

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science